文献速递治疗药物监测与药物基因组学

西班牙低干预临床试验十年趋势:比例仍低但CTIS实施未见明显影响

Low-intervention clinical trials in Spain: Do they progress?
PubMed 文献 · Br J Clin Pharmacol · 2025-12-17

该研究基于西班牙临床研究注册库2014至2023年数据,描述低干预临床试验(LICTs)特征。8497项注册试验中仅3.8%(322项)为LICTs,2023年比例未见下降,CTIS实施未见明显影响。LICTs多为非商业资助、单中心、IV期、随机但盲法较少的设计。

要点

  • 西班牙十年注册试验中LICTs仅占3.8%,比例仍低。
  • LICTs多为非商业资助、单中心、IV期随机试验,盲法设计较少。
  • 2023年CTIS实施未见LICTs比例下降。

核心结论

  • LICTs在西班牙获批临床试验中仍占比较小,设计稳健性有提升空间,CTIS实施未见明显影响LICTs活动。

主要发现

  • 2014至2023年REec共注册8497项临床试验,其中仅3.8%(N=322)被归类为LICTs。
  • 2023年LICTs总体比例未见下降。
  • 大多数LICTs由非商业实体申办,主要资金来自申办方自有资源。
  • LICTs常见为单中心IV期研究,评估已上市药品。
  • 主要目标以疗效和/或安全性为主,药物经济学、药物遗传学、药物基因组学和生物等效性作为主要目标相对少见。

临床怎么用

  • 提示临床药学智能体在解读LICTs证据时需注意其多为单中心、开放标签设计,稳健性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Low-Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non-commercial clinical trials (NCCTs); the mandatory implementation of CTIS in 2023 may have impacted LICTs feasibility. Our aim was to describe the main characteristics of LICTs approved in Spain over a ten-year period. METHODS: Cross-sectional descriptive analysis of LICTs registered between 2014 and 2023, in the Spanish Clinical Studies Registry (REec) database, mandatory to all authorized trials. RESULTS: Between January 2014 and December 2023, 8497 clinical trials were registered in REec, of which only 3.8% (N = 322) were classified as LICTs. No drop in the overall proportion of LICTs was seen in 2023. Most LICTs were sponsored by non-commercial entities and funded primarily through sponsors' own resources. LICTs were frequently monocentric phase IV studies evaluating commercialized medicinal products. The principal objectives of the trials included efficacy and/or safety, while pharmacoeconomics, pharmacogenetics, pharmacogenomics and bioequivalence were comparatively infrequent as main objectives. Most trial designs were randomized, but blinded trials were less frequent, and only a minority were placebo-controlled. CONCLUSIONS: Despite their critical role in establishing effectiveness and safety of authorized medicinal products in pragmatic clinical settings, LICTs still constitute a relatively small proportion of all clinical trials approved in Spain, and their designs have area for improvement in terms of robustness. There was no apparent effect of CTIS implementation on LICTs activity.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Delgado-Espinoza CE, Cortés Pestana MJ, Amaro K, et al. Low-intervention clinical trials in Spain: Do they progress? Br J Clin Pharmacol. 2025. PMID: 41406957. doi:10.1002/bcp.70409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。